SG10201907367QA - Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor - Google Patents
Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactorInfo
- Publication number
- SG10201907367QA SG10201907367QA SG10201907367QA SG10201907367QA SG10201907367QA SG 10201907367Q A SG10201907367Q A SG 10201907367QA SG 10201907367Q A SG10201907367Q A SG 10201907367QA SG 10201907367Q A SG10201907367Q A SG 10201907367QA SG 10201907367Q A SG10201907367Q A SG 10201907367QA
- Authority
- SG
- Singapore
- Prior art keywords
- plp
- dependent enzyme
- pharmaceutical composition
- cofactor
- erythrocytes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y206/00—Transferases transferring nitrogenous groups (2.6)
- C12Y206/01—Transaminases (2.6.1)
- C12Y206/01005—Tyrosine transaminase (2.6.1.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y404/00—Carbon-sulfur lyases (4.4)
- C12Y404/01—Carbon-sulfur lyases (4.4.1)
- C12Y404/01011—Methionine gamma-lyase (4.4.1.11)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Botany (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1451100A FR3017299B1 (fr) | 2014-02-12 | 2014-02-12 | Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201907367QA true SG10201907367QA (en) | 2019-09-27 |
Family
ID=50729647
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201907367QA SG10201907367QA (en) | 2014-02-12 | 2015-02-12 | Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor |
| SG11201606264SA SG11201606264SA (en) | 2014-02-12 | 2015-02-12 | Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201606264SA SG11201606264SA (en) | 2014-02-12 | 2015-02-12 | Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10046009B2 (es) |
| EP (2) | EP3104875B1 (es) |
| JP (1) | JP6563958B2 (es) |
| KR (1) | KR102354103B1 (es) |
| CN (2) | CN111358941B (es) |
| AU (2) | AU2015217045B2 (es) |
| BR (1) | BR112016017337B1 (es) |
| CA (1) | CA2938469C (es) |
| CL (1) | CL2016002020A1 (es) |
| ES (1) | ES2808849T3 (es) |
| FR (1) | FR3017299B1 (es) |
| IL (1) | IL246941B (es) |
| JO (1) | JO3522B1 (es) |
| MX (1) | MX2016010235A (es) |
| RU (2) | RU2744659C2 (es) |
| SG (2) | SG10201907367QA (es) |
| WO (1) | WO2015121348A2 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2930665A1 (en) | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| FR3017299B1 (fr) | 2014-02-12 | 2018-05-18 | Erytech Pharma | Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur |
| CA2944492A1 (en) | 2014-04-01 | 2015-10-08 | Rubius Therapeutics, Inc. | Methods and compositions for immunomodulation |
| EP3187190A1 (en) | 2015-12-31 | 2017-07-05 | Erytech Pharma | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion |
| SG11201805253SA (en) | 2016-01-11 | 2018-07-30 | Rubius Therapeutics Inc | Compositions and methods related to multimodal therapeutic cell systems for cancer indications |
| BR112018074716A2 (pt) | 2016-06-02 | 2019-03-12 | Sanofi | conjugados de um agente farmacêutico e porção capaz de ligar-se a uma proteína sensível à glicose |
| MX2020000265A (es) | 2017-07-07 | 2020-07-22 | Epicentrx Inc | Composiciones para la administración parenteral de agentes terapéuticos. |
| US11001826B2 (en) | 2017-10-19 | 2021-05-11 | Anticancer, Inc. | Orally administered composition to lower serum methionine levels and method of use |
| WO2019106122A1 (en) | 2017-12-01 | 2019-06-06 | Sanofi | Novel conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| EP3880309A1 (en) | 2018-11-15 | 2021-09-22 | Erytech Pharma | Synergistic combinations of methionine depletion agents and immune checkpoint modulators |
| CN114007627A (zh) | 2019-04-26 | 2022-02-01 | 鲁比厄斯治疗法股份有限公司 | 包含去核类红细胞的缓冲组合物 |
| CN114127252A (zh) | 2019-05-24 | 2022-03-01 | 鲁比厄斯治疗法股份有限公司 | 生成去核红系细胞的方法 |
| KR20220093196A (ko) | 2019-11-04 | 2022-07-05 | 루비우스 테라퓨틱스, 아이엔씨. | 타우린 또는 하이포타우린을 사용하여 제핵 적혈구 세포를 생성하는 방법 |
| WO2021092052A1 (en) | 2019-11-04 | 2021-05-14 | Rubius Therapeutics, Inc. | Methods of generating enucleated erythroid cells using myo-inositol |
| EP4149440A1 (en) | 2020-05-11 | 2023-03-22 | Erytech Pharma | Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof |
| TW202241470A (zh) | 2021-01-08 | 2022-11-01 | 美商盧比亞斯治療公司 | 治療人類個體腫瘤之方法 |
| TW202241471A (zh) | 2021-01-08 | 2022-11-01 | 美商盧比亞斯治療公司 | 提高個體中NKp30陽性淋巴球的方法及其用途 |
| WO2022197548A1 (en) | 2021-03-14 | 2022-09-22 | Rubius Therapeutics, Inc. | Methods of increasing nkg2d-positive lymphocytes in a subject and uses thereof |
| JP2024519906A (ja) * | 2021-05-21 | 2024-05-21 | コデクシス， インコーポレイテッド | 操作されたメチオニンガンマリアーゼバリアント |
| TW202317179A (zh) | 2021-06-03 | 2023-05-01 | 美商盧比亞斯治療公司 | 在個體中治療ｈｐｖ１６－陽性或ｈｐｖ１６－相關的癌症之方法 |
| CN113481253B (zh) * | 2021-06-09 | 2022-05-24 | 连云港杰瑞药业有限公司 | 生物催化制备磷酸吡哆醛的方法 |
| WO2023067200A1 (en) | 2021-10-24 | 2023-04-27 | Erytech Pharma | Asparaginase encapsulated in red blood cells for the treatment of pancreatic cancer |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1354204A (fr) | 1963-01-22 | 1964-03-06 | Auxiliaire De L Entpr Soc | Dispositif de prévention d'accident pour benne de chargement notamment d'une bétonnière |
| FR2529463B1 (fr) * | 1982-07-05 | 1986-01-10 | Centre Nat Rech Scient | Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus |
| US5631271A (en) * | 1986-11-29 | 1997-05-20 | Serfontein; Willem J. | Methods and preparations for the treatment and prophylaxis of metabolic disturbances |
| US5254572A (en) * | 1987-11-27 | 1993-10-19 | Vesta Medicines (Pty) Ltd. | Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed |
| EP0978560B1 (en) | 1997-03-13 | 2007-01-31 | Shionogi & Co., Ltd. | Process for producing l-methionine gamma-lyase crystals |
| AU2002211512A1 (en) * | 2000-10-06 | 2002-04-15 | Millennium Pharmaceuticals, Inc. | 25219, a novel human aminotransferase and uses therefor |
| AU2004288128A1 (en) * | 2003-07-31 | 2005-05-19 | Anticancer, Inc. | The use of PLP with PEG-rMETase in vivo for enhanced efficacy |
| FR2873925B1 (fr) * | 2004-08-05 | 2006-10-13 | Erytech Pharma Soc Par Actions | Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes |
| FR2884717B1 (fr) | 2005-04-25 | 2009-07-03 | Erytech Pharma Soc Par Actions | Erythrocytes renfermant de l'arginine deiminase |
| RU2362572C2 (ru) * | 2007-07-17 | 2009-07-27 | Юрий Георгиевич Каминский | Способ снижения концентрации аммиака в крови с помощью аммоцитов и инкапсулированной глутаминсинтетазы |
| FR2919804B1 (fr) | 2007-08-08 | 2010-08-27 | Erytech Pharma | Composition et vaccin therapeutique anti-tumoral |
| FR2925339B1 (fr) | 2007-12-24 | 2010-03-05 | Erytech Pharma | Medicament pour le traitement du cancer du pancreas |
| EP2242507B1 (en) | 2008-02-13 | 2013-02-20 | Erytech Pharma | Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease |
| FR2928270B1 (fr) | 2008-03-10 | 2011-01-21 | Erytech Pharma | Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os |
| FR2938332B1 (fr) | 2008-11-07 | 2011-11-25 | Erytech Pharma | Test predictif de la neutralisation de l'activite asparaginase |
| CN101429506A (zh) * | 2008-12-15 | 2009-05-13 | 吉林大学 | 基于红细胞载体的fish-in-net固定化酶 |
| FR2944106B1 (fr) | 2009-04-03 | 2012-09-28 | Erytech Pharma | Methode de dosage de l'inositol hexaphosphate (ihp). |
| CA2778669C (en) | 2009-10-27 | 2019-04-16 | Erytech Pharma | Composition to induce specific immune tolerance |
| CN104394884A (zh) * | 2012-03-21 | 2015-03-04 | 爱瑞泰克药物公司 | 用于治疗急性髓细胞白血病(aml)的药剂 |
| FR3005420B1 (fr) | 2013-05-07 | 2015-09-18 | Erytech Pharma | Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues. |
| EP2813234A1 (en) | 2013-06-11 | 2014-12-17 | Erytech Pharma | Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof |
| FR3017299B1 (fr) | 2014-02-12 | 2018-05-18 | Erytech Pharma | Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur |
| EP3187190A1 (en) * | 2015-12-31 | 2017-07-05 | Erytech Pharma | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion |
-
2014
- 2014-02-12 FR FR1451100A patent/FR3017299B1/fr active Active
-
2015
- 2015-02-12 RU RU2019123935A patent/RU2744659C2/ru active
- 2015-02-12 CA CA2938469A patent/CA2938469C/en active Active
- 2015-02-12 BR BR112016017337-6A patent/BR112016017337B1/pt active IP Right Grant
- 2015-02-12 MX MX2016010235A patent/MX2016010235A/es unknown
- 2015-02-12 SG SG10201907367QA patent/SG10201907367QA/en unknown
- 2015-02-12 CN CN202010182496.4A patent/CN111358941B/zh active Active
- 2015-02-12 EP EP15705563.3A patent/EP3104875B1/en active Active
- 2015-02-12 RU RU2016133315A patent/RU2697086C2/ru active
- 2015-02-12 SG SG11201606264SA patent/SG11201606264SA/en unknown
- 2015-02-12 CN CN201580007812.1A patent/CN106255506B/zh active Active
- 2015-02-12 WO PCT/EP2015/052962 patent/WO2015121348A2/en active Application Filing
- 2015-02-12 US US15/117,588 patent/US10046009B2/en active Active
- 2015-02-12 EP EP20173043.9A patent/EP3718562A1/en active Pending
- 2015-02-12 AU AU2015217045A patent/AU2015217045B2/en active Active
- 2015-02-12 JO JOP/2015/0030A patent/JO3522B1/ar active
- 2015-02-12 JP JP2016568136A patent/JP6563958B2/ja active Active
- 2015-02-12 ES ES15705563T patent/ES2808849T3/es active Active
- 2015-02-12 KR KR1020167022067A patent/KR102354103B1/ko active IP Right Grant
-
2016
- 2016-07-25 IL IL246941A patent/IL246941B/en active IP Right Grant
- 2016-08-10 CL CL2016002020A patent/CL2016002020A1/es unknown
-
2018
- 2018-02-21 AU AU2018201237A patent/AU2018201237B2/en active Active
- 2018-08-13 US US16/102,171 patent/US10780126B2/en active Active
-
2020
- 2020-09-22 US US17/028,383 patent/US11458170B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201907367QA (en) | Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor | |
| PH12020500066A1 (en) | Carboxamides as modulators of sodium channels | |
| MY189466A (en) | Methods of modulating drug plasma levels using erythrohydroxybupropion | |
| AU2018247351B2 (en) | Methods and compositions for treatment of demyelinating diseases | |
| MX2013006591A (es) | Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas. | |
| AU2012284088A8 (en) | Heterocyclic compounds and uses thereof | |
| MX2018004328A (es) | Composiciones farmaceuticas estabilizantes de camptotecina. | |
| WO2012174158A3 (en) | Administration of benzodiazepine | |
| WO2014015056A3 (en) | Anti-mucus drugs and uses therefor | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
| EP3972691A4 (en) | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DRUG OVERDOSE | |
| PH12016502234A1 (en) | Process for obtaining optically active pirlindole enantiomers and salts thereof | |
| MX2014014814A (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
| NZ726131A (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| MX355719B (es) | Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano. | |
| MX2014014816A (es) | Composicion farmaceutica para tratar inflamacion y dolor. | |
| MX2014014817A (es) | Compuestos para el tratamiento de inflamacion y dolor. | |
| WO2013038200A3 (en) | Neurodevelopmental disorders | |
| WO2011106378A3 (en) | Oral b12 therapy | |
| WO2019098691A3 (ko) | 음이온성 약물 함유 약제학적 조성물의 동결건조 조성물 및 방법 | |
| WO2013127539A3 (de) | Pharmazeutische formulierung enthaltend flupirtin | |
| MX2016010919A (es) | 4-bencilsulfonil-2-butenonitrilo. | |
| MY174063A (en) | Poly-l-glutamic acid drug carrier for targeting and treating kidney diseases | |
| UA74769U (ru) | Способ лечения больных со стеатозом печени, совмещенным с хроническим безкаменным холециститом |